DrugBiological
Efanesoctocog alfa clinical trials
Also written BIVV001 and Altuviiio.
- studies test it
- 12
- open now
- 1
- in phase 3
- 5
- first study started
- 2017
Keep track of what changes. Save the efanesoctocog alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
12 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 1
- Phase 3
- 5
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Swedish Orphan Biovitrum (5) · Bioverativ, a Sanofi company (5) · Sanofi (2)
Studies
Open first, then newest update. How each study uses efanesoctocog alfa is read from its arms, and is right about nine times in ten.
Testing it · 12
- Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyRecruitingPhase 4SanofiNCT06941870Written as Efanesoctocog alfa
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingPhase 3Swedish Orphan BiovitrumNCT06716814Written as Efanesoctocog alfa
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingPhase 4Swedish Orphan BiovitrumNCT06940830Written as Efanesoctocog alfa
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AActive, not recruitingPhase 3Bioverativ, a Sanofi companyNCT04644575Written as efanesoctocog alfa (BIVV001)
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedPhase 3Swedish Orphan BiovitrumNCT05817812Written as Efanesoctocog alfa
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedPhase 1Swedish Orphan BiovitrumNCT06579144Written as Efanesoctocog alfa
- A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruitingPhase 4Swedish Orphan BiovitrumNCT06752850Written as Efanesoctocog alfa
- To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)CompletedPhase 1Bioverativ, a Sanofi companyNCT04770935Written as efanesoctocog alfa (BIVV001)
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompletedPhase 1SanofiNCT05042440Written as Efanesoctocog alfa
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia ACompletedPhase 3Bioverativ, a Sanofi companyNCT04161495Written as efanesoctocog alfa (BIVV001)
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia ACompletedPhase 3Bioverativ, a Sanofi companyNCT04759131Written as efanesoctocog alfa (BIVV001)
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)CompletedPhase 1/2Bioverativ, a Sanofi companyNCT03205163Written as BIVV001 (Low Dose)
Codes
What other systems call efanesoctocog alfa · ClinicalTrials.gg INT018357
- UNII (FDA) WH7BHQ0RB4EFANESOCTOCOG ALFAOne source FDA
- NCI Thesaurus C174933Efanesoctocog AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WH7BHQ0RB4 | EFANESOCTOCOG ALFA | One source FDA |
| NCI Thesaurus | C174933 | Efanesoctocog Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.